[ALXN] Alexion Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 28.04 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 127.19 Change: 1.34 (1.06%)
Ext. hours: Change: 0 (0%)

chart ALXN

Refresh chart

Strongest Trends Summary For ALXN

ALXN is in the long-term up 2052% in 24 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding224.02 M EPS3.07 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 17.14% Sales Growth - Q/Q0.14% P/E37.13
P/E To EPS Growth P/S12.36 P/BV7.97 Price/Cash Per Share14.56
Price/Free Cash Flow55.69 ROA13.34% ROE16.74% ROI15.36%
Current Ratio4.92 Quick Ratio4.61 Long Term Debt/Equity0.05 Debt Ratio0.17
Gross Margin90.72% Operating Margin33.65% Net Profit Margin25.97% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities5.07 M Cash From Investing Activities-48.42 M Cash From Operating Activities23.03 M Gross Profit584.2 M
Net Profit170.22 M Operating Profit181.08 M Total Assets13.17 B Total Current Assets2.53 B
Total Current Liabilities769.17 M Total Debt3.5 B Total Liabilities4.61 B Total Revenue636.21 M
Technical Data
High 52 week139.01 Low 52 week93.94 Last close111.7 Last change-0.03%
RSI80.37 Average true range4.01 Beta1.14 Volume2.37 M
Simple moving average 20 days7.77% Simple moving average 50 days-1.17% Simple moving average 200 days-6.46%
Performance Data
Performance Week1.58% Performance Month2.07% Performance Quart-8.06% Performance Half-16.82%
Performance Year-8.04% Performance Year-to-date14.73% Volatility daily2.7% Volatility weekly6.05%
Volatility monthly12.39% Volatility yearly42.94% Relative Volume244.27% Average Volume1.74 M
New High New Low

News

2019-03-19 09:48:54 | See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

2019-03-12 10:29:25 | See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

2019-03-11 21:28:07 | Dicerna Pharmaceuticals Inc DRNA Q4 2018 Earnings Conference Call Transcript

2019-03-11 14:17:37 | If You Had Bought Alexion Pharmaceuticals NASDAQ:ALXN Stock Five Years Ago, You’d Be Sitting On A 27% Loss, Today

2019-03-08 09:05:00 | Alexion Announces Publication of Interim Data from Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy and Safety of SOLIRIS® Eculizumab in Adult Patients with Generalized Myasthenia Gravis in Muscle & Nerve

2019-03-06 09:30:02 | Why Is Alexion ALXN Up 9.7% Since Last Earnings Report?

2019-03-06 08:35:00 | Analysis: Positioning to Benefit within Bristol-Myers Squibb, AAR, Central Garden & Pet, Alexion Pharmaceuticals, Tribune Media, and Civitas Solutions — Research Highlights Growth, Revenue, and Consolidated Results

2019-03-06 04:43:38 | Mass. life science leaders say outgoing FDA head was an 'advocate for modernization'

2019-03-05 16:30:00 | Alexion to Present at the Cowen 39th Annual Health Care Conference

2019-03-01 13:46:04 | Final trades: Six Flags, Alexion Pharma, Alphabet, American Express & the financials

2019-02-28 14:44:21 | These 10 New Drugs Expected In 2019 Are On The Blockbuster Track

2019-02-28 08:30:00 | Alexion Employees Raise Hands to Raise Awareness and #RallyforRare on Rare Disease Day

2019-02-26 12:15:58 | America's 'inefficient' health care system is driving our fiscal instability: Powell

2019-02-25 15:25:04 | 5 Clinical Stage Biotech Stocks to Buy

2019-02-22 14:51:00 | FDA Grants Priority Review and Accepts sBLA of SOLIRIS® Eculizumab as a Treatment for Patients with Neuromyelitis Optica Spectrum Disorder NMOSD

2019-02-21 16:30:00 | Alexion to Present at the 8th Annual SVB Leerink Global Healthcare Conference

2019-02-21 09:00:00 | Alexion Pharma and Carnival Among Stocks Billionaire Ray Dalio Added in Q4

2019-02-20 16:45:56 | IBD 50 Stocks To Watch: Top Biotech Alexion Moves Into Buy Range

2019-02-14 13:00:06 | Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

2019-02-13 09:11:02 | The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion

2019-02-12 15:18:08 | Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp

2019-02-12 09:00:00 | Alexion Announces Creation of New Roles on Executive Leadership Team

2019-02-11 08:39:01 | Is Alexion ALXN a Great Growth Stock?

2019-02-08 08:05:26 | See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

2019-02-07 07:55:00 | Recent Analysis Shows Alexion Pharmaceuticals, Plug Power, Rayonier Advanced Materials, SunCoke Energy, Rhythm Pharmaceuticals, and Armstrong Flooring Market Influences — Renewed Outlook, Key Drivers of Growth

2019-02-06 09:50:52 | Alexion Pharmaceuticals Inc ALXN Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-02-04 16:13:42 | Biotech Reports Solid Fourth Quarter, But Slips On Mixed Guidance

2019-02-04 16:11:33 | Stocks rise amid next batch of corporate earnings

2019-02-04 15:29:37 | Edited Transcript of ALXN earnings conference call or presentation 4-Feb-19 1:00pm GMT

2019-02-04 14:46:38 | Alexion Pharmaceuticals ALXN Q4 2018 Earnings Conference Call Transcript

2019-02-04 12:45:05 | Alexion's ALXN Earnings Beat Estimates in Q4, Shares Up

2019-02-04 11:57:05 | Stocks making the biggest moves midday: Papa John's, Sysco, Clorox & more

2019-02-04 10:38:03 | Economic & Earnings Data Deluge

2019-02-04 10:26:03 | Q4 Earnings Soldier on Gamely: GOOGL, CLX & More

2019-02-04 08:54:18 | Stocks Open Mixed, Dow Jones Drags Ahead Of Alphabet Earnings

2019-02-04 08:39:00 | Here's Why Alexion Pharmaceuticals Gained 26.3% in January

2019-02-04 08:30:01 | Alexion ALXN Tops Q4 Earnings and Revenues Beat Estimates

2019-02-04 07:48:04 | Stocks making the biggest moves premarket: Papa John's, Spotify, Clorox, Yelp & more

2019-02-04 06:52:34 | Alexion: 4Q Earnings Snapshot

2019-02-04 06:33:00 | Evolus Rises Midday as Botox Drama Unfolds

2019-02-04 06:30:00 | Alexion Reports Fourth Quarter and Full Year 2018 Results

2019-02-01 14:06:00 | Why Amgen Should Buy Alexion Pharmaceuticals

2019-02-01 06:30:00 | Alexion to Highlight Rare Disease Portfolio at Investor Day

2019-01-31 19:26:12 | Alexion ALXN to Report Q4 Earnings: What's in the Cards?

2019-01-31 06:30:00 | Alexion and Caelum Biosciences Announce Collaboration to Develop Targeted Therapy for Light Chain AL Amyloidosis

2019-01-31 06:30:00 | Fortress Biotech Announces CAEL-101 Strategic Partnership with Alexion Pharmaceuticals

2019-01-29 11:10:04 | Alexion's Ultomiris Meets Primary Endpoint in aHUS Study

2019-01-28 10:01:57 | Stock Market Tumbles On Caterpillar Earnings Miss, Nvidia Warning

2019-01-28 06:30:00 | Alexion Announces Positive Top-Line Results from Phase 3 Study of ULTOMIRIS™ Ravulizumab-cwvz in Complement Inhibitor-Naïve Patients with atypical Hemolytic Uremic Syndrome aHUS

2019-01-25 07:55:00 | Analysis: Positioning to Benefit within Cigna, Alexion Pharmaceuticals, Synchrony Financial, Global Medical REIT, Investors Real Estate Trust, and CPI Card Group — Research Highlights Growth, Revenue, and Consolidated Results